Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia

• Published in: Journal of clinical psychopharmacology Vol. 43; no. 2; p. 97
• Main Authors: Bogers, Jan P A M, Schulte, Peter F J, Broekman, Theo G, de Haan, Lieuwe
• Format: Journal Article
• Language: English
• Published: United States 01.03.2023
• Subjects: Aged; Antipsychotic Agents - adverse effects; Clozapine - therapeutic use; Feasibility Studies; Humans; Middle Aged; Schizophrenia - drug therapy; Schizophrenia, Treatment-Resistant
• ISSN: 1533-712X
• DOI: 10.1097/JCP.0000000000001657

It is unknown whether increasing the clozapine plasma level to 400, 750, or even 1000 ng/mL is a feasible and effective strategy in patients with treatment-resistant schizophrenia (TRS). We investigated this in long-stay patients with TRS. In long-stay TRS patients, doses of clozapine were increased gradually to reach target plasma levels of 400, 750, or 1000 ng/mL, depending on the clinical response and tolerability. After an effective or tolerated level was reached, positive and negative syndrome scale scores were evaluated after 3 months and 1 year. Twenty-eight patients were included. Overall, 54% of the patients, and especially patients 60 years and older, could not achieve one of the clozapine target levels because of adverse effects. Three physically vulnerable patients died, probably not directly related to clozapine use. Although only 21% of patients achieved a more than 20% reduction in total symptoms at the 1-year follow-up, the mean severity of positive symptoms decreased from 18.18 to 15.10 ( P < 0.01). The largest decrease in positive symptoms was seen in TRS patients who achieved a plasma level of 750 ng/mL of clozapine. Most TRS patients older than 60 years could not tolerate high clozapine levels and so this should not be attempted in older or otherwise physically vulnerable patients. Increasing clozapine levels to approximately 750 ng/mL in middle-aged patients with longstanding TRS may modestly reduce the severity of positive symptoms and improve the response rate.